Details for: SPRYCEL
Company: BRISTOL-MYERS SQUIBB CANADA
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02293129 | SPRYCEL | DASATINIB (DASATINIB MONOHYDRATE) | 20 MG | TABLET | ORAL |
| 02293137 | SPRYCEL | DASATINIB (DASATINIB MONOHYDRATE) | 50 MG | TABLET | ORAL |
| 02293145 | SPRYCEL | DASATINIB (DASATINIB MONOHYDRATE) | 70 MG | TABLET | ORAL |
| 02360810 | SPRYCEL | DASATINIB (DASATINIB MONOHYDRATE) | 80 MG | TABLET | ORAL |
| 02320193 | SPRYCEL | DASATINIB (DASATINIB MONOHYDRATE) | 100 MG | TABLET | ORAL |
| 02360829 | SPRYCEL | DASATINIB (DASATINIB MONOHYDRATE) | 140 MG | TABLET | ORAL |
Summary Reports
Summary Basis of Decision
Summary Safety Review - Bcr-Abl Tyrosine Kinase Inhibitors - Assessing the Potential Harm to the Fetus
Summary Safety Review - Bcr-Abl Tyrosine Kinase Inhibitors - Assessing the Potential Harm to the Fetus
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.